Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.

ASCO 2018 Rechallenge with bevacizumab in ovarian cancer

Dr. Sandro Pignata, oncologist and president of the Multicentre Italian Trial in Ovarian cancer (MITO) group, explains the results of the MITO 16b trial. This study evaluated whether the addition of bevacizumab to a platinum-based chemotherapy prolongs survival for recurrent ovarian cancer patients who had already received it during first line.

  • Sponsors

    This program is editorially independent and is financially made possible by

Related items

Congresnieuws 27/06/2018

ASCO 2018 Results of the TAILORx trial

Joseph Sparano, oncologist at Montefiore Medical Center, explains the results of the TAILORx trial, which he presented during the plenary session at ASCO 2018. This trial attempted to incorporate a gene expression test into clinic decision making for hormone receptor positive breast cancer.

Congresnieuws 22/03/2018

ESMO 2017 in-depth: Neoadjuvant chemotherapy in cervical cancer

This year the ESMO congress took place in Madrid from 8 - 12 September. Sudeep Gupta, Professor of Medical Oncology at Tata Memorial Hospital in Mumbai, explains the design and results of his trial, that examined whether neoadjuvant chemotherapy followed by surgical removal of the tumour could improve outcomes in patients with locally advanced cervical cancer compared to standard treatment with chemoradiation.